Thyroid nodules are focal lesions of the thyroid gland that can be distinguished from the surrounding parenchyma and are detected by palpation or, more commonly, by ultrasound. In the vast majority of cases, they are benign lesions associated with colloid hyperplasia, cystic degeneration, or nodular remodeling in the setting of goiter. However, their clinical relevance derives from the need to exclude thyroid carcinoma and identify nodules capable of causing thyroid dysfunction or compressive symptoms. In practical terms, modern management aims to combine diagnostic accuracy with a reduction in unnecessary procedures, avoiding both the overdiagnosis of indolent microcarcinomas and the underestimation of clinically significant disease.
The assessment of thyroid nodules requires the integration of medical history, physical examination, biochemical evaluation, primarily TSH, high-resolution ultrasound, and, when indicated, fine-needle aspiration with reporting according to the Bethesda System. Ultrasound-based risk stratification systems, such as EU-TIRADS and ACR TI-RADS, play a central role in determining which nodules should undergo fine-needle aspiration and which should be monitored.
Thyroid nodules are among the most common findings in clinical endocrinology. The prevalence of palpable nodules is relatively low, but the widespread use of ultrasound has shown that thyroid nodularity is extremely common in the general population, with rates increasing with age and female sex. Ultrasound identifies nodules in a large proportion of asymptomatic individuals, whereas only a minority present as a palpable mass or cause local symptoms. This discrepancy forms the basis of the contemporary approach: not every nodule that is detected requires an invasive diagnostic pathway, and decisions must be guided by clinical risk and ultrasound characteristics.
The risk that a nodule is malignant is not uniform and depends on demographic, medical history, and ultrasound variables. Guidelines emphasize that the probability of carcinoma among clinically evaluated nodules falls within a clinically relevant range, which justifies careful diagnostic assessment despite the predominance of benign lesions. The risk profile changes substantially when specific predisposing factors are present, and these factors must be identified before imaging findings are interpreted.
Among the most important clinical risk factors is exposure to ionizing radiation during childhood or adolescence, including cervical radiotherapy and certain environmental exposures, which increase the risk of papillary carcinoma and lower the threshold for concern even in small nodules. Family history is another relevant factor, particularly the presence of differentiated thyroid carcinoma in first-degree relatives or genetic syndromes associated with endocrine neoplasms. In these settings, assessment tends to be more intensive and follow-up more frequent.
The nutritional and geographical context, particularly iodine status, influences the prevalence of nodularity and goiter. In iodine-deficient areas, thyroid nodules may be more common and are more frequently multinodular, reflecting chronic remodeling driven by thyrotropic stimulation and heterogeneous follicular responses. Functional autonomy is also more likely in these settings, creating implications that connect the epidemiology of thyroid nodules with the pathophysiology of functioning nodules. This issue becomes crucial when TSH levels are reduced.
Factors such as female sex and advanced age are associated with a higher prevalence of nodules but are not, in themselves, specific markers of malignancy. Conversely, certain clinical presentations at a younger age, particularly in the presence of predisposing factors, require greater caution because the prognostic consequences of delayed diagnosis may be more significant. Pregnancy and the postpartum period may also increase the likelihood that nodules are detected because of physiological changes and closer clinical surveillance, although they do not automatically imply an increased risk of cancer, which must always be estimated using objective criteria.
An expanding area concerns the “iatrogenic” epidemiology of thyroid nodules. On the one hand, the increasing use of neck imaging for unrelated indications results in incidental diagnoses, with a risk of excessive procedures for indolent lesions. On the other hand, therapies and conditions that alter the hypothalamic-pituitary-thyroid axis or iodine homeostasis may influence the size and behavior of pre-existing nodules. In this context, the quality of ultrasound triage and adherence to risk-based fine-needle aspiration thresholds are essential to avoid unnecessary interventions.
Thyroid nodularity is not a single entity but a common morphological outcome of different biological processes that converge in the formation of a focally distinct lesion. From an etiological perspective, many lesions are associated with colloid hyperplasia and repeated cycles of follicular growth and involution, often occurring in functionally heterogeneous thyroid tissue. In other cases, the nodule represents a follicular adenoma, a cystic lesion resulting from hemorrhagic degeneration, or an inflammatory process that focally remodels the glandular structure.
Thyroid physiology is organized around the follicle, where iodide is taken up and organified and where thyroglobulin acts as a matrix for the synthesis of T4 and T3. Any condition that chronically increases proliferative stimulation, particularly through signals mediated by TSH or local growth factors, may promote the development of follicular clones with a relative proliferative advantage. In nodular goiter, clonal heterogeneity and differential responses to thyrotropic stimulation result in uneven growth, with hyperplastic areas, involutional areas, and cystic degeneration, producing the mosaic pattern typical of multinodularity.
A crucial pathogenetic event is the development of functional autonomy in a proportion of nodules, in which follicular cells acquire the ability to produce hormones partially independently of central regulation. The biological basis of this autonomy is often associated with alterations in the TSH receptor signaling pathway and the cyclic adenosine monophosphate cascade, which provide a functional and proliferative advantage. Clinically, autonomy becomes relevant when it suppresses TSH and changes the diagnostic strategy, because when TSH is low, the average probability of malignancy is lower and diagnostic evaluation must include functional assessment.
From a neoplastic perspective, malignant transformation involves the activation of proliferative signaling pathways and the progressive loss of differentiation controls, producing phenotypes ranging from well-differentiated papillary carcinoma to less differentiated forms. In clinical practice, the objective is not to explain the oncogenesis of every nodule in abstract terms, but to recognize that ultrasound and cytology are tools used to estimate the probability that a particular morphological and cytological phenotype corresponds to a clinically significant neoplasm. This is the point at which pathogenesis translates into clinical decision-making: high-risk ultrasound patterns and high-risk cytological categories require a more clearly defined pathway, whereas low-risk lesions can be monitored.
The pathophysiology of thyroid nodules also includes local and systemic effects. Locally, large nodules or multinodular goiters may cause compressive symptoms involving the trachea and esophagus, swallowing disturbances, a foreign-body sensation, and occasionally dysphonia, particularly when the goiter extends retrosternally. Systemically, functioning nodules or multinodularity with diffuse autonomy may lead to overt or subclinical hyperthyroidism, with significant cardiovascular and metabolic consequences, particularly in older patients. These aspects explain why nodule management cannot be limited to excluding cancer but must also include a comprehensive assessment of thyroid function, volume, and the lesion’s evolutionary trajectory.
Most thyroid nodules are clinically silent and are detected incidentally or during evaluations performed for other reasons. When a nodule is discovered incidentally, the most delicate step is translating an anatomical finding into a clinical probability, preventing anxiety associated with the word “nodule” from automatically leading to invasive procedures. When symptoms are present, they mainly depend on the size, location, presence of a cystic component, rate of growth, and functional status of the nodule.
During history-taking, the patient may report the appearance of a swelling in the anterior neck, often noticed in the mirror or by another person. In many cases, the mass is stable and painless, but rapid growth, particularly when accompanied by pain, may suggest intranodular hemorrhage or, more rarely, an aggressively growing disorder. Symptoms such as dysphagia, a sensation of cervical constriction, breathing difficulty during exertion or while lying supine, and recent-onset snoring suggest a compressive effect or retrosternal involvement that may not be apparent on inspection alone.
The medical history must include signs and symptoms of hormonal dysfunction. If the nodule is associated with hyperthyroidism, the patient may report palpitations, heat intolerance, weight loss, tremor, insomnia, and reduced exercise tolerance. In the presence of concomitant hypothyroidism, which may coexist in autoimmune settings, fatigue, weight gain, and cold intolerance may occur. The relationship between a nodule and thyroid function is not automatic, and clinical findings must always be integrated with biochemical data, avoiding conclusions based solely on symptoms.
On physical examination, palpation may identify a solitary nodule, a diffusely enlarged thyroid gland, or multinodularity. Consistency, mobility, and possible fixation to deeper tissues are useful but not definitive findings, because palpation has limited sensitivity and many characteristics are shared by benign and malignant lesions. It is essential to look for signs that, when present, increase the priority of the diagnostic pathway, such as suspicious lateral cervical lymphadenopathy, dysphonia, vocal cord paralysis, or signs of tracheal compression. Clinical and ultrasound correlation remains the key step in translating physical examination findings into a rational strategy.
The psychological component is not secondary: the detection of a nodule may generate anxiety and requests for “preventive removal.” Effective clinical management requires explaining that the risk of cancer is selective and that choosing fine-needle aspiration or follow-up does not represent minimization, but rather an approach based on risk stratification. In this way, the medical consultation becomes an orderly process: from history-taking to suspicion, from suspicion to diagnostic investigations, and from investigations to shared decisions.
Clinical suspicion of a thyroid nodule arises in three main scenarios: a finding on palpation, symptoms compatible with a cervical mass or compression, and an incidental finding on imaging. In all cases, the priority is not to confirm that a nodule “exists,” but to establish whether the finding requires urgent assessment, a standard diagnostic pathway, or simple monitoring. Clinical reasoning must begin with risk factors and clinical warning signs that alter the pretest probability.
Suspicion of a higher-risk lesion increases in the presence of radiation exposure at a young age, a significant family history of differentiated thyroid carcinoma, reported rapid growth, recent-onset dysphonia, or signs of lymph node involvement. The association between a thyroid nodule and persistent or atypical lateral cervical lymphadenopathy also shifts the focus toward a complete ultrasound evaluation of the neck, including the lymph node compartments, because the identification of a suspicious lymph node may provide an indication for fine-needle aspiration even when the thyroid nodule is small.
In asymptomatic patients, suspicion of clinical significance is driven mainly by ultrasound. However, even before imaging, TSH is an important guiding parameter: reduced TSH suggests functional autonomy, a setting in which the diagnostic strategy often includes additional functional assessment and in which cancer risk is interpreted according to specific principles. Conversely, normal or elevated TSH does not identify the risk of malignancy but directs the patient toward a pathway in which ultrasound and cytology become the cornerstones of stratification.
A further clinical threshold is related to volume-dependent symptoms. A benign nodule may be clinically relevant because of compression or cosmetic impact, particularly in multinodular goiter. In these cases, even in the absence of suspected cancer, the diagnostic work-up must be complete because treatment depends on size, composition, whether solid or cystic, retrosternal extension, and relationships with the trachea and esophagus. Suspicion therefore does not simply mean “risk of cancer,” but rather “the need to define the nature, function, and consequences” of the nodule.
The diagnostic assessment of thyroid nodules follows a pathway that integrates clinical evaluation, thyroid function, imaging, and cytology. Guidelines converge on several essential steps: measuring TSH as the initial biochemical test, performing high-resolution thyroid ultrasound with systematic evaluation of the nodule characteristics and cervical lymph nodes, and using standardized ultrasound risk stratification systems, such as EU-TIRADS or ACR TI-RADS, to determine when fine-needle aspiration should be performed.
TSH measurement represents a key decision point. If TSH is reduced or suppressed, the probability that the nodule is hyperfunctioning increases, and the diagnostic work-up generally includes functional assessment, typically with scintigraphy, to distinguish hot, cold, or indeterminate nodules. This step is clinically relevant because hyperfunctioning nodules are less frequently malignant and because management of hormone excess may become the priority. If TSH is normal or elevated, stratification is based mainly on ultrasound and cytology, with a more limited role for scintigraphy.
Ultrasound is the central diagnostic tool because it allows assessment of the size, composition, echogenicity, margins, calcifications, shape, and vascularity of the nodule, as well as possible signs of extrathyroidal extension and lateral cervical lymph node involvement. Standardized reporting reduces variability and allows reproducible decisions. In practice, a high-risk ultrasound pattern or a high TI-RADS category does not automatically mandate fine-needle aspiration, but makes it appropriate when the nodule exceeds specific size thresholds or when high-risk clinical features coexist.
When fine-needle aspiration is indicated, cytology must be reported according to the Bethesda System, which links each diagnostic category to an estimated risk of malignancy and a management recommendation. This structure avoids the most common misunderstanding: interpreting the cytological result as an absolute “yes or no” answer. Intermediate categories, particularly indeterminate findings, require integration with ultrasound, clinical history, and, in selected centers, molecular testing of the cytological sample, as proposed by European guidelines specifically addressing molecular diagnosis in indeterminate nodules.
Management of nodules with benign cytology does not end after the first fine-needle aspiration. Ultrasound follow-up is guided by ultrasound risk and changes in size: significant growth or the development of new suspicious characteristics may indicate that fine-needle aspiration should be repeated, whereas prolonged stability reduces the need for frequent monitoring. In parallel, nodules with nondiagnostic cytology require reassessment of the sampling technique and often repeat fine-needle aspiration, ideally under ultrasound guidance and with assessment of sample adequacy.
A further diagnostic step is assessment of the overall thyroid context. The presence of autoimmune thyroiditis, which may be identified through a diffuse ultrasound pattern and thyroid autoantibodies, may alter the clinical interpretation of symptoms and thyroid function. In addition, large or retrosternal goiters may require further imaging to assess their extent and define the degree of compression. In urgent situations involving respiratory compromise or significant dysphonia, the diagnostic process must be expedited and coordinated with otolaryngological assessment and, when indicated, laryngeal endoscopy.
The classification of thyroid nodules is useful because it transforms an anatomical description into a clinical prediction and management plan. The first distinction is morphological: solid nodule, cystic nodule, or mixed nodule. Purely cystic nodules are often benign and may become clinically relevant because of recurrence or compressive symptoms. Solid nodules require more rigorous stratification based on ultrasound characteristics and cytology. Composition also influences therapeutic options because certain minimally invasive procedures have preferential indications for benign cystic or solid nodules.
A second classification is topographical and quantitative: solitary nodule versus multinodularity. Multinodular goiter is common and does not automatically imply a higher cancer risk for each individual nodule, but it makes triage more complex because the dominant or most suspicious nodules must be selected, avoiding the error of systematically biopsying every lesion. TI-RADS systems are designed specifically to guide this selection by focusing on nodules that combine ultrasound risk with clinically significant dimensions.
From a functional perspective, nodules may be nonfunctioning or functioning, with the latter category including hyperfunctioning nodules responsible for subclinical or overt thyrotoxicosis. Functional classification depends on the integration of TSH levels with functional imaging and also affects the cytological strategy, because when a nodule is hyperfunctioning, the indication for fine-needle aspiration is generally more selective and linked to specific ultrasound or clinical findings.
Finally, clinical classification may focus on the risk of malignancy, the risk of volume-related complications, and the risk of thyroid dysfunction. This three-dimensional perspective allows comprehensive management: a benign but large nodule may require treatment, whereas a small nodule with high-risk ultrasound features may require fine-needle aspiration and targeted decisions. Severity therefore does not correspond solely to size, but to the interaction between cancer risk, functional impact, and temporal trajectory.
Treatment of thyroid nodules must be proportionate to the risk and expected benefit, avoiding excessive intervention for indolent lesions while ensuring adequate control of symptomatic nodules or those associated with cancer risk. The most common strategy for asymptomatic benign nodules is observation, with scheduled ultrasound follow-up based on the ultrasound risk profile and dimensional stability. This approach is consistent with natural history data showing that most benign nodules remain stable or grow slowly, with only a minority displaying significant growth over time.
For benign nodules that cause symptoms or cosmetic concerns, options include surgery and selected minimally invasive treatments. Surgery is indicated when there are significant compressive symptoms, substantial retrosternal extension, rapid recurrence after drainage, or persistent diagnostic uncertainty despite a complete work-up. The choice between lobectomy and more extensive surgery depends on the nodular context, residual thyroid function, risk of hypothyroidism, and oncological requirements. In parallel, ablative techniques such as radiofrequency or laser are available for selected benign nodules, particularly solid lesions, whereas ethanol ablation may be considered for recurrent cystic nodules. These strategies aim to reduce nodule volume and symptoms while preserving thyroid parenchyma and reducing surgical risks in selected patients.
Treatment of nodules with suspicious or malignant cytology is predominantly surgical, with the extent of surgery guided by the overall clinical picture, estimated risk, and tumor characteristics once a diagnosis has been established. In indeterminate nodules, treatment is the stage at which the pathway must be genuinely personalized: integration of ultrasound risk, Bethesda category, possible molecular tests, and patient preferences guides the choice among surveillance, repeat fine-needle aspiration, diagnostic surgery, or alternative strategies in expert centers. In this setting, it is essential to recognize that a proportion of indeterminate lesions correspond to neoplasms with indolent behavior and that the objective is not to maximize the number of surgical procedures, but to maximize appropriateness.
Suppressive levothyroxine therapy aimed at reducing the size of benign nodules is not generally recommended in modern clinical practice because its average benefits are modest and the risk of iatrogenic subclinical hyperthyroidism, with adverse effects on the heart and bones, may outweigh any advantage, particularly in older patients. The safer approach is to focus on follow-up, correction of any hormonal dysfunction, and targeted treatment of nodules that cause symptoms or have a clinically relevant risk profile.
Follow-up of thyroid nodules is a structured process that depends on ultrasound risk, cytological findings, and clinical history. In nodules that do not undergo fine-needle aspiration, ultrasound monitoring aims to confirm stability and detect any morphological changes that might alter the indication for the procedure. The most recent European guidelines emphasize the importance of reducing excessively frequent examinations in low-risk nodules, particularly when stability has been documented over time, in order to limit a diagnostic cascade that, despite good intentions, may be unnecessary.
In nodules with benign cytology, monitoring must integrate two dimensions: growth and changes in ultrasound characteristics. Growth alone does not indicate malignancy because many benign lesions enlarge, but significant growth or a qualitative change in the ultrasound pattern may justify reassessment with repeat fine-needle aspiration. Assessment of the lymph nodes is also part of follow-up: the appearance of suspicious lymphadenopathy requires more extensive reassessment even when the primary nodule was initially considered low risk.
In nodules with nondiagnostic cytology, the strategy includes repeating fine-needle aspiration under optimal technical conditions because inadequate sampling is not a reassuring result. If nondiagnostic findings persist and the nodule has suspicious ultrasound characteristics, the residual risk requires consideration of additional options, including diagnostic surgery in selected cases. In indeterminate nodules, follow-up or intervention must be planned consistently with ultrasound risk and changes in the cytological category, avoiding serial repetitions that have no effect on clinical decision-making.
An often underestimated aspect of follow-up is patient education. Patients must understand the warning signs that warrant earlier reassessment, such as perceived growth, new-onset dysphonia, compressive symptoms, or signs of thyrotoxicosis. At the same time, it must be explained that ultrasound stability and benign cytology are robust findings that allow less intensive monitoring, reducing anxiety and unnecessary medicalization.
Finally, follow-up must include reassessment of thyroid function when clinically indicated, because functional autonomy may emerge over time and because certain treatments, changes in iodine intake, or intercurrent conditions may alter the biochemical profile. Monitoring is therefore not confined to measuring the diameter of the nodule but follows a comprehensive endocrinological framework involving structure, function, risk, and symptoms.
The prognosis of thyroid nodules is excellent in most cases because the majority are benign and remain stable or progress slowly. Even when differentiated thyroid carcinoma is present, the outcome is often favorable if it is appropriately diagnosed and treated, although prognosis depends on histological type, extent, and biological profile. In the setting of thyroid nodules, prognosis depends primarily on the appropriateness of the diagnostic pathway: identifying nodules that require fine-needle aspiration and treatment while avoiding unnecessary procedures in low-risk lesions.
The most concerning complication in a patient with a thyroid nodule is not the “presence of the nodule” itself, but the clinical event that occurs when inadequate stratification leads to underdiagnosis of clinically significant neoplasms or, conversely, when excessive procedures result in unnecessary interventions and iatrogenic complications. Preventing this dual risk is the reason guidelines have progressively shifted their focus toward specific ultrasound criteria and size thresholds.
Mechanical complications include tracheal or esophageal compression, particularly in multinodular goiter and retrosternal extensions, with possible respiratory symptoms and dysphagia. Some nodules, especially cystic lesions, may undergo intralesional hemorrhage, causing acute pain and a sudden increase in volume. From a functional perspective, nodular autonomy may cause subclinical or overt thyrotoxicosis, increasing the risk of arrhythmias, worsening pre-existing heart disease, and reducing bone mass, particularly in vulnerable individuals.
Procedural complications include those related to fine-needle aspiration, which are generally rare and mild, such as local pain and hematoma, but may become clinically relevant if the patient is taking anticoagulant or antiplatelet therapy and preparation is not managed appropriately. Surgical complications include the risk of hypoparathyroidism and recurrent laryngeal nerve injury, which can have significant functional consequences and must be considered in the risk-benefit assessment, particularly when surgery is indicated for benign nodules. Ablative procedures, although less invasive, may also cause local adverse effects and require careful patient selection and technical expertise.
Overall, prognosis depends on the ability to establish a rational pathway: ultrasound risk stratification, appropriate use of cytology, integration of molecular testing when genuinely useful, and targeted treatment of nodules that cause symptoms, dysfunction, or significant cancer risk. Within this framework, thyroid nodule management becomes a model of risk-based medicine, in which the best outcome derives from the precision of decisions rather than the intensity of procedures.